Skip to main content
SpringerLink
Log in

Ultrafiltration and Heart Failure

  • Chapter
  • First Online:
Managing the Kidney when the Heart is Failing

  • 727 Accesses

Abstract

Acute decompensated heart failure (ADHF) is a clinical scenario that stems from the underlying pathophysiology of fluid overload. Diuretic therapy has been the mainstay of restoration of homeostatic balance toward euvolemia but has limited success in the setting of diuretic resistance. With increased mortality in ADHF attributed to renal impairment and morbidity related to repeat hospitalization being a concern, strategy to effectively reduce congestion without putting renal function in further jeopardy has been demonstrated with ultrafiltration (UF). This review illustrates the pathophysiology and pitfalls of hypervolemia and examines the data validating the extracorporeal removal of fluid with UF.

Originally published in Bakris, The Kidney in Heart Failure, ISBN: 978-1-4614-3693-5

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Writing Group Members, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–215.

    Article  PubMed  Google Scholar 

  2. Adams Jr KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–16.

    Article  PubMed  Google Scholar 

  3. O’Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail. 2005;11(3):200–5.

    Article  PubMed  Google Scholar 

  4. Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008;10(2):188–95.

    Article  PubMed  Google Scholar 

  5. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442–63.

    Article  PubMed  CAS  Google Scholar 

  6. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148(1):43–51.

    Article  PubMed  Google Scholar 

  7. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(4):384–416.

    Article  PubMed  Google Scholar 

  8. Krumholz HM, Keenan PS, Brush Jr JE, et al. Standards for measures used for public reporting of efficiency in health care: a scientific statement from the American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research and the American College of Cardiology Foundation. Circulation. 2008;118(18):1885–93.

    Article  PubMed  Google Scholar 

  9. Schrier RW, Berl T. Nonosmolar factors affecting renal water excretion (first of two parts). N Engl J Med. 1975;292(2):81–8.

    Article  PubMed  CAS  Google Scholar 

  10. Schrier RW, Cadnapaphornchai MA, Umenishi F. Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonists. Heart Dis. 2001;3(3):210–4.

    Article  PubMed  CAS  Google Scholar 

  11. De Angelis N, Fiordaliso F, Latini R, et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol. 2002;34(12):1655–65.

    Article  PubMed  Google Scholar 

  12. Rocha R, Stier Jr CT, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141(10):3871–8.

    Article  PubMed  CAS  Google Scholar 

  13. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.

    Article  PubMed  CAS  Google Scholar 

  14. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.

    Article  PubMed  CAS  Google Scholar 

  15. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43(1): 61–7.

    Article  PubMed  Google Scholar 

  16. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13(8):599–608.

    Article  PubMed  Google Scholar 

  17. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs. 1990;39 Suppl 4:10–21 [discussion 22–4].

    Article  PubMed  Google Scholar 

  18. Maxwell MH, Breed ES, Schwartz IL. Renal venous pressure in chronic congestive heart failure. J Clin Invest. 1950;29(3):342–8.

    Article  PubMed  CAS  Google Scholar 

  19. Kastner PR, Hall JE, Guyton AC. Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II. Am J Physiol. 1982;243(3):F260–4.

    PubMed  CAS  Google Scholar 

  20. Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest. 2003;33(9):769–78.

    Article  PubMed  CAS  Google Scholar 

  21. Morsing P, Stenberg A, Casellas D, et al. Renal interstitial pressure and tubuloglomerular feedback control in rats during infusion of atrial natriuretic peptide (ANP). Acta Physiol Scand. 1992;146(3):393–8.

    Article  PubMed  CAS  Google Scholar 

  22. Firth JD, Raine AEG, Ledingham JGG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet. 1988;331(8593):1033–6.

    Article  Google Scholar 

  23. Morley D, Brozena SC. Assessing risk by hemodynamic profile in patients awaiting cardiac transplantation. Am J Cardiol. 1994;73(5):379–83.

    Article  PubMed  CAS  Google Scholar 

  24. Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol. 1984;54(1):147–52.

    Article  PubMed  CAS  Google Scholar 

  25. Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007;9(9):872–8.

    Article  PubMed  Google Scholar 

  26. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53(7):582–8.

    Article  PubMed  Google Scholar 

  27. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294(13):1625–33.

    Article  PubMed  Google Scholar 

  28. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51(13):1268–74.

    Article  PubMed  Google Scholar 

  29. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7): 589–96.

    Article  PubMed  Google Scholar 

  30. Patterson JH, Adams Jr KF, Applefeld MM, Corder CN, Masse BR. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy. 1994;14(5):514–21.

    PubMed  CAS  Google Scholar 

  31. Sherman LG, Liang CS, Baumgardner S, Charuzi Y, Chardo F, Kim CS. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther. 1986;40(5):587–94.

    Article  PubMed  CAS  Google Scholar 

  32. Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106(1):90–6.

    Article  PubMed  CAS  Google Scholar 

  33. Faris Rajaa F, Flather M, Purcell H, Poole-Wilson PA, Coats Andrew JS. Diuretics for heart failure. Cochrane Database Syst Rev. 2006;(1). http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003838/frame.html.

  34. McCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol. 2004;44(6):1301–7.

    Article  PubMed  CAS  Google Scholar 

  35. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387–95.

    Article  PubMed  CAS  Google Scholar 

  36. Vargish T, Benjamin R, Shenkman L. Deafness from furosemide. Ann Intern Med. 1970;72(5):761.

    PubMed  CAS  Google Scholar 

  37. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96(3–4):132–43.

    Article  PubMed  CAS  Google Scholar 

  38. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med. 1983;102(3):450–8.

    PubMed  CAS  Google Scholar 

  39. Knauf H, Mutschler E. Functional state of the nephron and diuretic dose-response—rationale for low-dose combination therapy. Cardiology. 1994;84 Suppl 2:18–26.

    Article  PubMed  Google Scholar 

  40. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med. 1991;114(10):886–94.

    PubMed  CAS  Google Scholar 

  41. Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994;71(2):146–50.

    Article  PubMed  CAS  Google Scholar 

  42. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28(2):376–82.

    Article  PubMed  CAS  Google Scholar 

  43. Kramer WG, Smith WB, Ferguson J, et al. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol. 1996;36(3):265–70.

    PubMed  CAS  Google Scholar 

  44. Silverstein ME, Ford CA, Lysaght MJ, Henderson LW. Treatment of severe fluid overload by ultrafiltration. N Engl J Med. 1974;291(15):747–51.

    Article  PubMed  CAS  Google Scholar 

  45. Paganini EP, Fouad F, Tarazi RC, Bravo EL, Nakamoto S. Hemodynamics of isolated ultrafiltration in chronic hemodialysis patients. Trans Am Soc Artif Intern Organs. 1979;25: 422–5.

    Article  PubMed  CAS  Google Scholar 

  46. Rimondini A, Cipolla CM, Della Bella P, et al. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med. 1987;83(1):43–8.

    Article  PubMed  CAS  Google Scholar 

  47. Simpson IA, Simpson K, Rae AP, Boulton-Jones JM, Allison ME, Hutton I. Ultrafiltration in diuretic-resistant cardiac failure. Ren Fail. 1987;10(2):115–9.

    Article  PubMed  CAS  Google Scholar 

  48. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96(3):191–9.

    Article  PubMed  CAS  Google Scholar 

  49. Canaud B, Leray-Moragues H, Garred LJ, et al. Slow isolated ultrafiltration for the treatment of congestive heart failure. Am J Kidney Dis. 1996;28(5):S67–73.

    Article  Google Scholar 

  50. Marenzi G, Grazi S, Giraldi F, et al. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am J Med. 1993;94(1):49–56.

    Article  PubMed  CAS  Google Scholar 

  51. Blake P, Hasegawa Y, Khosla MC, Fouad-Tarazi F, Sakura N, Paganini EP. Isolation of “myocardial depressant factor(s)” from the ultrafiltrate of heart failure patients with acute renal failure. ASAIO J. 1996;42(5):M911–5.

    Article  PubMed  CAS  Google Scholar 

  52. Dormans TP, Huige RM, Gerlag PG. Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. Heart. 1996;75(4):349–51.

    Article  PubMed  CAS  Google Scholar 

  53. Canaud B, Leblanc M, Leray-Moragues H, Delmas S, Klouche K, Beraud JJ. Slow continuous and daily ultrafiltration for refractory congestive heart failure. Nephrol Dial Transplant. 1998;13 Suppl 4:51–5.

    Article  PubMed  Google Scholar 

  54. Costanzo MR, Saltzberg M, O’Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46(11):2047–51.

    Article  PubMed  Google Scholar 

  55. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46(11):2043–6.

    Article  PubMed  Google Scholar 

  56. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675–83.

    Article  PubMed  CAS  Google Scholar 

  57. Ali SS, Olinger CC, Sobotka PA, et al. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail. 2009;15(1):1–4.

    Article  PubMed  CAS  Google Scholar 

  58. Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31.

    Article  PubMed  CAS  Google Scholar 

  59. Libetta C, Sepe V, Zucchi M, et al. Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrol Dial Transplant. 2007;22(7):2013–9.

    Article  PubMed  CAS  Google Scholar 

  60. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140(6):840–7.

    Article  PubMed  CAS  Google Scholar 

  61. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. 1991;90(3):353–9.

    Article  PubMed  CAS  Google Scholar 

  62. Whellan DJ, Greiner MA, Schulman KA, Curtis LH. Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. Circ Cardiovasc Qual Outcomes. 2010;3(1): 33–40.

    Article  PubMed  Google Scholar 

  63. Bradley SM, Levy WC, Veenstra DL. Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis. Circ Cardiovasc Qual Outcomes. 2009;2(6):566–73.

    Article  PubMed  Google Scholar 

  64. Ross EA, Kazory A. Overcoming financial constraints of ultrafiltration for heart failure. Am J Cardiol. 2010;105(10):1504–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Division, Internal Medicine Department, The Ohio State University Medical Center, Columbus, OH, USA

    Paul Chacko & Donald Kikta Jr.

  2. Ohio State University Medical Center, 473 West 12th Avenue, Room 110P, Columbus, OH, 43210-1252, USA

    William T. Abraham

Authors
  1. Paul Chacko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald Kikta Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William T. Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William T. Abraham .

Editor information

Editors and Affiliations

  1. ASH Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medical Center, 5841 S. Maryland Avenue, MC1027, Chicago, 60637, Illinois, USA

    George L. Bakris

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Chacko, P., Kikta, D., Abraham, W.T. (2012). Ultrafiltration and Heart Failure. In: Bakris, G. (eds) Managing the Kidney when the Heart is Failing. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3691-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3691-1_7

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-3690-4

  • Online ISBN: 978-1-4614-3691-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation